Non‐interferon‐based therapy: an option for amelioration of necro‐inflammation in hepatitis C patients who cannot afford interferon therapy

Abstract

Twenty-four weeks N-IFN-BT achieved a fourfold-higher ETBR and a tenfold-higher SBR compared with silymarin therapy, which reflects an improvement of necroinflammatory activity as proven by repeat histopathology.